Reply to: "Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries"

J Hepatol. 2017 Dec;67(6):1350-1352. doi: 10.1016/j.jhep.2017.07.019. Epub 2017 Aug 5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antiviral Agents*
  • Developing Countries
  • England
  • Hepatitis C*
  • Hepatitis C, Chronic*
  • Humans
  • State Medicine


  • Antiviral Agents